AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
Details of the event is as follows:
Oppenheimer 34th Annual Healthcare Life Sciences Conference (virtual)
Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Wednesday, February 14, 2024 at 10:40am ET.
A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial candidate is epetraborole, which we are studying as a once-daily, oral treatment with a novel mechanism of action for patients with nontuberculous mycobacteria (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.
Landlord Studio, the leading property management accounting software for self-managing landlords announced its new free listing syndication feature in partnership with Zillow and Zumper.
Charles Chan, CEO of Landlord Studio said, "We're delighted to...
TIER IV, a pioneer in open-source autonomous driving (AD) technology, today announced an exciting initiative aimed at shaping the future of highway trucking. In response to driver shortage challenges facing Japan's cargo industry, the company is set...
FLJ Group Limited (the "Company"), today announced that it has received a letter dated April 25, 2024 (the "Determination Letter") from the listing qualifications department staff (the "Staff") of The Nasdaq Stock Market ("Nasdaq"), notifying that...
watchTowr, a leader in external attack surface management (EASM) technology and fuelled by watchTowr Labs, a renowned vulnerability R&D capability, has formed a strategic partnership with JupiterOne. JupiterOne is a leader in cyber asset attack...
Premia Partners, a leading ETF provider from Hong Kong, announces today fee reduction of its Premia Vietnam ETF (the ETF) and change of the underlying index to S&P Vietnam Core Index (USD) NTR (the index) with immediate effect.
Total expense ratio...
East Side Games Group ("ESGG" or the "Company"), Canada's leading free-to-play mobile game group, will release its first quarter 2024 financial results on Wednesday, May 8, 2024, after market close. Following the release, the Company will hold a...
